INmune Bio Inc

NASDAQ:INMBUnited States

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation.

Contact Information

Headquarters

225 Ne Mizner Blvd, Suite 640BOCA RATON, FL, United States 33432

Phone

858-964-3720

Fax

---

Executives

President, Chief Executive Officer, Director

Raymond Tesi

Chief Financial Officer

David Moss

Chief Scientific Officer

Mark Lowdell

Independent Director

Marcia Allen

Independent Director

J. Kelly Ganjei